| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CCR2; CKR2; CCR-2; CCR2A; CCR2B; CKR2A; CKR2B; CMKBR2; MCP-1-R; CC-CKR-2 |
| Entrez GeneID | 729230 |
| clone | 3B6B1 |
| WB Predicted band size | 41.9kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD192 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD192(CCR2)抗体的3篇参考文献及其摘要信息：
---
1. **文献名称**: *Targeting CCR2 with its antagonist suppresses tumor growth and metastasis in a melanoma mouse model*
**作者**: Qian BZ et al.
**摘要**: 该研究开发了一种抗CCR2单克隆抗体，并在黑色素瘤小鼠模型中验证其作用。结果显示，阻断CCR2可显著减少肿瘤相关巨噬细胞(TAMs)的浸润，抑制肿瘤生长和肺转移，表明CCR2抗体在癌症免疫治疗中的潜力。
---
2. **文献名称**: *A human CCR2 antibody delays atherosclerosis in hyperlipidemic mice*
**作者**: Brodmerkel CM et al.
**摘要**: 研究者通过抑制CCR2信号，评估其对抗动脉粥样硬化的效果。实验显示，抗CCR2抗体能减少单核细胞向血管病变部位的迁移，延缓动脉粥样硬化斑块的形成，提示其在心血管疾病中的治疗价值。
---
3. **文献名称**: *CCR2 inhibition alters the immune microenvironment and improves checkpoint blockade in pancreatic cancer*
**作者**: Sanford DE et al.
**摘要**: 该研究结合抗CCR2抗体与PD-1抑制剂治疗胰腺癌模型。结果显示，CCR2阻断减少免疫抑制性骨髓细胞的数量，增强T细胞活性，显著提高免疫治疗响应率，为联合疗法提供了实验依据。
---
这些文献涵盖了CCR2抗体在肿瘤、心血管疾病及免疫联合治疗中的应用，展示了其在不同病理环境中的作用机制及潜在疗效。
CD192. also known as CCR2 (C-C chemokine receptor type 2), is a G protein-coupled receptor primarily expressed on monocytes, macrophages, and certain T-cell subsets. It binds to chemokines such as CCL2 (MCP-1), CCL7. and CCL12. playing a critical role in mediating immune cell migration to sites of inflammation, infection, or injury. CCR2 is implicated in various pathological conditions, including chronic inflammation, autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis), atherosclerosis, and cancer metastasis.
CD192 antibodies are tools designed to target and modulate CCR2 activity. They are used in research to study receptor-ligand interactions, immune cell trafficking, and disease mechanisms. Therapeutically, CCR2-blocking antibodies have been explored to inhibit pro-inflammatory pathways or disrupt the tumor microenvironment by limiting monocyte infiltration. For instance, in cancer, CCR2 inhibition may reduce tumor-associated macrophage recruitment, potentially suppressing tumor growth and metastasis. Conversely, some antibody-based strategies aim to enhance immune responses by redirecting immune cells to diseased tissues.
Despite promising preclinical results, clinical translation faces challenges, including redundancy in chemokine signaling and off-target effects. Current efforts focus on optimizing antibody specificity, affinity, and delivery to improve therapeutic efficacy. CD192 antibodies remain pivotal in both understanding CCR2 biology and developing targeted therapies for inflammation-related and oncologic disorders.
×
